Prevalence of COVID-19 Infection Among HCW in a French University Hospital (EXPOCOVIA)

April 22, 2021 updated by: University Hospital, Lille

Prevalence of SARS-Cov2 Infection Among HCW in Lille University Hospital

The objective of this study is to determine the prevalence of SARS-Cov2 infection among health care workers exposed of Lille University Hospital, to describe its evolution during the epidemic taking into account the influence of occupational and environmental exposure determinants.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

900

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • France
      • Lille, France, 59037
        • Hop Claude Huriez Chu Lille

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Health Care workers with or without symptoms suggestive of a COVID-19 infection

Description

Inclusion Criteria:

- Health Care workers with or without symptoms suggestive of a COVID-19 infection

Exclusion Criteria:

  • HCW working off-site at the CHU de Lille
  • HCW on sick leave.
  • HCW outside the Lille University Hospital temporarily coming as reinforcements in the context of the epidemic.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
High-risk
staff working in a unit specifically for patients infected or suspected of being infected with SARS-Cov2
Other: self-administered questionnaire
Every weeks during 2 months, clinical and occupational questionnaire are performed among a cohort of HCW exposed to covid occupational exposure
Other Names:
  • a specifically designed self-administered questionnaire
Diagnostic test: SARS-Cov2 testing
Every weeks during 2 month, SARS-Cov2 RT-PCR, serological testing are performed among a cohort of HCW exposed to covid occupational exposure
Medium- risk
staff working in a unit that can accommodate patients infected or suspected of being infected with SARS-Cov2, i.e., all care services that do not fall into the high-risk group.
Other: self-administered questionnaire
Every weeks during 2 months, clinical and occupational questionnaire are performed among a cohort of HCW exposed to covid occupational exposure
Other Names:
  • a specifically designed self-administered questionnaire
Diagnostic test: SARS-Cov2 testing
Every weeks during 2 month, SARS-Cov2 RT-PCR, serological testing are performed among a cohort of HCW exposed to covid occupational exposure
Low-risk
off-patient staff
Other: self-administered questionnaire
Every weeks during 2 months, clinical and occupational questionnaire are performed among a cohort of HCW exposed to covid occupational exposure
Other Names:
  • a specifically designed self-administered questionnaire
Diagnostic test: SARS-Cov2 testing
Every weeks during 2 month, SARS-Cov2 RT-PCR, serological testing are performed among a cohort of HCW exposed to covid occupational exposure

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
the prevalence of SARS- Cov2 infection Health Care Worker with or without symptoms suggestive of a COVID-19 infection
Time Frame: at 2 months
at 2 months

Secondary Outcome Measures

Outcome Measure
Time Frame
the prevalence of SARS- Cov2 infection Health Care Worker with or without symptoms suggestive of a COVID-19 infection
Time Frame: once week during 2 months
once week during 2 months
Occupational exposures associated with the SARS-Cov2 infection
Time Frame: once week during 2 months
once week during 2 months
Environmental exposures associated with the SARS-Cov2 infection
Time Frame: once week during 2 months
once week during 2 months
immunologic status of health Care Worker
Time Frame: once week during 2 months
once week during 2 months
inflammatory biomarkers status of Health Care Worker
Time Frame: once week during 2 months
once week during 2 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University Hospital, Lille

Collaborators

Fondation Santé Roquette

Investigators

  • Principal Investigator: Annie SOBASZEK, MD, University Hospital, Lille

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 15, 2020

Primary Completion (Actual)

July 9, 2020

Study Completion (Actual)

July 9, 2020

Study Registration Dates

First Submitted

April 28, 2020

First Submitted That Met QC Criteria

April 28, 2020

First Posted (Actual)

May 1, 2020

Study Record Updates

Last Update Posted (Actual)

April 23, 2021

Last Update Submitted That Met QC Criteria

April 22, 2021

Last Verified

April 1, 2021

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2020_35
  • 2020-A00951-38 (Other Identifier: ID-RCB number,ANSM)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Sars-CoV2

Clinical Trials on self-administered questionnaire

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Indonesia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe